BC G Unresponsive Non- Muscle Invasive Bladder Cancer

Size: px
Start display at page:

Download "BC G Unresponsive Non- Muscle Invasive Bladder Cancer"

Transcription

1 BC G Unresponsive Non- Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology ScoA Department of Urology Baylor College of Medicine, Houston, Texas InternaHonal Bladder cancer Update January 24, 2017

2

3 Disclosures Clinical trials Endo, FKD, VivenHa NCI/SWOG Roche/Genentech, JBL Advisory Board Ferring Consultant Biocancell, UroGen, Vaxiion 3

4 Learning Objec=ves To understand current status and outcomes with BCG To describe post BCG treatment states and specifically BCG unresponsive disease To understand current Guideline statements To understand which pahents should be treated with salvage radical cystectomy To apply appropriate decision making regarding the use of salvage intravesical therapy To be aware of clinical trial ophons 4

5 BCG Indica=ons Any pahent with high risk NMIBC TaHG, T1, Tis; mulhfocal and recurrent and >3cm TaLG First occurrence standard of care Recurrent BCG naïve BCG failure (induchon) if no indicahon for cystectomy or medically unfit FDA approved for CIS and high risk Ta,T1 5

6 Standard of Care SWOG BCG Maintenance Recurrence- Free Survival 2 year RFS 82% vs. 62% p without < maintenance 5 year RFS 60% vs. 41% without maintenance Lamm, DL et al, J Urol 163:1124,

7 Failure to Achieve a CR at 3 Months Status at 3 month cysto associated with outcome EORTC affirmed 3 years of maintenance as standard of care for high risk NMIBC Lerner, et al Secondary analysis of SWOG 8507 Urologic Oncology 27:155,

8 Outcomes Following BCG Table 3 Multivariable analysis of disease-related variables and the associated risk of treatment failure in BCG failure patients with (A) any recurrent CIS or (B) recurrent pure papillary disease treated with intravesical BCG/IFN. (N denotes sample size) Note: # signifies that there was no significant difference between these two groups (A) Treatment Failure Level N HR 95% CI P-value Number of Prior BCG Courses 2 courses <.01 1 courses 55 Ref Prior BCG Failure Interval <6 Months <.01 # 6 12 Months >12 Months 28 Ref Total 98 (B) Treatment Failure Kaplan-Meier plot of treatment success of intravesical BCG/IFN in BCG Failure patients with recurrent CIS stratified by prior BCG failure interval and number of prior BCG failures including number at-risk. Images in this article Both prior BCG therapy and interval from last BCG are independently associated with recurrence probability Steinberg, et al Bladder Cancer 2:215,

9 FDA/AUA/SUO Guidance Urology 83:262, /30/ /26/2015 9

10 BCG Unresponsive high risk NMIBC Recurrent/persistent high grade urothelial carcinoma ajer complehon of at least induchon and one cycle maintenance BCG ( 5+2 ) for high grade Ta/T1 or CIS Never achieved CR or recurred within 6 months of last BCG dose T1HG at first evaluahon ajer induchon BCG at least 5 of 6 induchon doses These pahents are extremely unlikely to respond to further BCG Lerner et al, Bladder Cancer 1:29, 2015)

11 Consider Extravesical Sites RetrospecHve analysis of 110 pahents with high- risk disease and BCG NMIBC repeatedly treated with intravesical BCG, No maintenance 52% had UUT and/or urethral carcinoma 48% had intravesical recurrence alone 11

12 Biopsies of the Prosta=c Urethra TUR biopsies at 5 and 7 o clock adjacent to the verumontanum detect CIS Verumontanum P ducts CIS 12

13 Importance of Prosta=c Urethra BCG treatment failed in 62 high- risk cases; pahents underwent cystectomy ProstaHc urethra TCC most important predictor of muscle- invasive cancer Hazard raho, 12.2 ( ) P =.003 Sampling from the urethra in high- risk pahents is essenhal T2 <T2 Huguet J, et al. Eur Urol. 2005;48:

14 Case 60yo male Prior history of NMIBC treated with BCG During workup for right ureter stricture PosiHve bladder wash cytology high grade Suspicious renal pelvis washing ureteroscopy negahve Cystoscopy no obvious papillary tumors Bladder biopsies - mulhfocal CIS of the bladder 14

15 Case (con=nued) ProstaHc urethra biopsies Duct and acinar CIS Minimal invasion peri- ductal soj Hssue RC + eplnd Path: Extensive bladder CIS pt0n0 (0/30) with CIS prostahc ducts/no invasion 1/25/17 15 Baylor College of Medicine

16 Cystectomy is the Standard of Care for Pa=ents Who are Medically Fit 16

17 Cystectomy is the Standard of Care for Pa=ents Who are Medically Fit ICUD 2012 The threat of progression remains real but comfortably low enough within the first 6 months of inihahng BCG to consider alternahves to cystectomy for those pahents unfit or not willing to undergo this standard management ophon (LOE 2, Grade B). In the case of any BCG non- response or failure, cystectomy is recommended (LOE 2a, Grade A). 17

18 Early vs. Delayed Cystectomy 105 pts, T1G3 with at least 2 risk factors CIS, large tumor, mulhfocality) 51 refused cystectomy and treated with BCG. All ulhmately had a delayed cystectomy (avg 11 months later) Cystectomy done at first sign of recurrence T1 or TIS or T2 (34%) Ø 5 yr CSS 83% vs. 67% Ganzinger Eur Urol 53:146,

19 Cystectomy in BCG Failure for CIS Long- term cancer control rates ophmal with RC n=52 with CIS only at the =me of RC All pahent underwent extended LND to IMA No pahent had lymph node metastasis 5- and 10- year RFS rates were 94% and 90%, Zahnder, et al BJU Int Jan

20 When BCG Fails the PaHent BCG/IFN Valrubicin only FDA approved drug Gemcitabine OpHmized MMC Gem/MMC Gem/Docetaxel Clinical trial 20

21 BCG plus Interferon Alpha MulHcenter phase II trial 213 pahents with CIS Ø PaHents with 2 or more prior courses of BCG or BCG- refractory did worse Rosevear, JUrol 186:817,

22 Valrubicin 80 pahents with CIS 39% had at least 2 prior courses of BCG Received 6 or 9 weeks of Valstar 35% NED at 3 months THINK (posihve cytology allowed) CR at 6 months 18% 7% disease free at 2 years Dinney et al Urol Onc 31:1635,2013

23 Gemcitabine SWOG S pahents all failed 2 courses BCG 89% high risk, 60% CIS 6 weekly treatments 2g in 100cc, then monthly x 12 Results: Ø 47% NED at 3 months Ø 28% conhnuously disease- free at 12 mos Skinner J Urol 190:1200,

24 Docetaxel 54 pahents All failed prior BCG 22 had only one prior course 83% high grade, 53% with CIS Recurrence- free Survival Barlow et al, J Urol 189:834, 2013

25 Device- assisted Chemotherapy Synergo microwave with MMC 1 51 pahents with CIS 34 failed prior BCG, 17 refractory (not reported separately) CR at 3 months 88% 22/45 (49%) recurred with median f/u 22 months 6 cystectomies ElectromoHve MMC (EMDA) promising US trials in BCG- recurrent pahents in planning phase 1 Witjes et al World J Urol 2009;27:319 25

26 Combina=on Chemotherapy 1g gemcitabine, then 40 mg MMC (sequenhal, 90 min each) 47 pahents - 76% intermed/high risk, 55% CIS - 17 no prior BCG (10 immunocompromised) - 55% >2 prior courses BCG 68% CR at 3 months 48 % NED at 1 year 38% NED at 2 years (20-25% for HG/CIS) CIS All pa=ents High grade Lighroot AJ, Urol Oncol 32:35, e

27 Gemcitabine/Docetaxel 45 pahents treated over 5 years InducHon only TaLG (4); TaHG (13) CIS (20); T1HG (8) 66% 54% 33% Steinberg, et al Bladder Cancer 1:65,

28 Dra] FDA Guidance November

29 Clinical Trial Design FDA Guidance Randomizing pahents with BCG- unresponsive disease to a minimally effechve drug as a concurrent control raises ethical concerns. Because effechve drugs are not available and the alternahve treatment is cystectomy, single- arm trials of pahents with BCG unresponsive CIS disease with or without papillary disease are appropriate. Primary endpoint should be complete response in pahents with CIS 29

30 Clinical Trials Ad- IFN gene therapy (FKD) SUO- CTC Viccinium (VivenHa) Atezolizumab (SWOG S Roche/GNE) Pembrolizumab (Merck) ABI- 009 Phase I/II (AADi LLC) Cabazitaxel, gemcitabine, and cisplahn Phase I (Columbia) BGJ 398 FGFR targeted therapy (MSKCC) ChemoXRT for T1 (RTOG 0926) 30

31 Ad- IFN (FKD/SUOCTC) A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rad- IFN/ Syn3) Administered Intravesically to PaHents with High Grade, BCG Unresponsive, NMIBC PI - Boorjian Primary aim: To evaluate the incidence of HG Event- Free Survival at 12 months Treatment: Ad/IFN 3 x 1011 vp/ml135 pahents; 35 responding pahents at 12 months (RR 25.2%, 95% CI = [18.1%, 33.4%])

32 Ad- IFN (FKD/SUOCTC) Intravesical dosing at 3 month intervals x 4; mos 1,4,7,10 Responding pahents may conhnue treatment year 2

33 S1605: Phase 2 trial of Atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. (PI Peter Black) Rationale: High risk NMIBC responds to immunotherapy PDL1 is expressed in NMIBC 1 Encouraging results in metastatic disease 2,3 Hypothesis: checkpoint molecules facilitate immune evasion in BCG-unresponsive NMIBC and this can be overcome with checkpoint inhibitors 1 Inman et al, Cancer Powles et al, Nature Rosenberg, Lancet 2016

34 Study Scheme BCG unresponsive Ta/T1/Tis (TURBT) Atezolizumab Atezolizumab Atezolizumab q 3 weeks Atezolizumab registration within 6 weeks of TURBT start therapy within 5 days of registration cysto cytol Atezolizumab Atezolizumab Atezolizumab Atezolizumab cysto biopsy cytol Atezolizumab maintenance q3wks for 9 cycles q 3 weeks 9 weeks* 21 weeks* (=6 months post TURBT) surveillance for 18 months 18 months * time is relative to first dose of atezolizumab

35 Take Home Message High risk disease any high grade Ta or T1 and any CIS BCG standard of care Maintenance therapy improves recurrence and progression- free survival No role for Interferon in BCG naïve pahents May be beneficial as salvage therapy 35

36 Take Home Message BCG Failure and Unresponsive states are high risk for understaging and progression to muscle invasive disease Radical cystectomy has a high probability of long term cancer control Intravesical therapy and clinical trials of new agents are appropriate for those pahents who do not need immediate cystectomy, refuse or are medically unfit for cystectomy 36

37 Aims & Scope Editors-in-Chief Seth P. Lerner Scott Department of Urology Baylor College of Medicine Houston, Texas, USA Dan Theodorescu University of Colorado Cancer Center Aurora, Colorado, USA To view the full Editorial Board, please visit: Bladder Cancer Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and lettersto-the-editor. In addition, the journal will also have a News and Views section for timely commentary. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the bladder and upper urinary tract. Journal Information ISSN (print) ISSN (online) The first issue (1:1) to be published in 2015 Open Access author fees waived for 2015 and 2016 In 2015 and 2016 freely available online Call for Papers Submit Your Article Submit manuscripts electronically via the mstracker online submission system at: For detailed author instructions please visit our website: submission-of-manuscripts

BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies

BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College of

More information

BCG Unresponsive NMIBC: What s Available?

BCG Unresponsive NMIBC: What s Available? BCG Unresponsive NMIBC: What s Available? Michael S. Cookson, MD, MMHC, FACS Professor and Chair Department of Urology University of Oklahoma TwiLer @uromc Professional Practice Gap Gap 1: There is incomplete

More information

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of

More information

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th

More information

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College

More information

Novel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia

Novel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia Novel therapeutic strategies for NMIBC Peter Black Vancouver Prostate Centre University of British Columbia Financial and Other Disclosures I have the following financial interests or relationships to

More information

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience Paul Gellhaus Assistant Clinical Professor Iowa??? none Disclosures Caveats Dr. Michael O Donnell

More information

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy

More information

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer Eila C. Skinner, MD Professor, Department of Urology Stanford University SWIU Winter Meeting January, 2015 Goals Minimize treatment for patients

More information

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of

More information

Intravesical Therapy for Bladder Cancer

Intravesical Therapy for Bladder Cancer Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology

More information

Issues in the Management of High Risk Superficial Bladder Cancer

Issues in the Management of High Risk Superficial Bladder Cancer Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma

More information

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

Current Experience with Intrapelvic/Intraureteral Irrigation/Ablative Therapy

Current Experience with Intrapelvic/Intraureteral Irrigation/Ablative Therapy Current Experience with Intrapelvic/Intraureteral Irrigation/Ablative Therapy Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine

More information

Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS

Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Objectives 1. Explore best practice diagnostic techniques 2.

More information

BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients

BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients Michael S. Cookson, MD, Professor and Chair Department of Urology University of Oklahoma Non-muscle Invasive Bladder Cancer Bladder

More information

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,

More information

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Jehonathan H Pinthus MD, Ph.D, FRCSC Associate Professor Department of Surgery/Urology McMaster University Life expectancy Current age

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or

More information

Controversies in the management of Non-muscle invasive bladder cancer

Controversies in the management of Non-muscle invasive bladder cancer Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic

More information

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D.

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be: Case 1 89 year old male with initial occurrence of gross hematuria Office flexible cystoscopy shows two papillary tumors with some surface necrosis Complete TURBT into muscle Florescence cysto shows two

More information

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney

More information

Options for first-line cisplatin-eligible patients

Options for first-line cisplatin-eligible patients The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.

More information

Urinary Bladder Cancer

Urinary Bladder Cancer Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b

More information

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member

More information

T1HG Bladder Cancer What is the Best Therapy?

T1HG Bladder Cancer What is the Best Therapy? T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction

More information

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert

More information

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Bladder Cancer 1 (2015) 65 72 DOI 10.3233/BLC-150008 IOS Press Research Report 65 Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Ryan

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer

Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer 1 Bladder Cancer Recurrence is common Progression is uncommon Progression is more important than recurrence There are indicators of recurrence

More information

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017

Role and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients

More information

Bacille-Calmette-Guerin non-responders: how to manage

Bacille-Calmette-Guerin non-responders: how to manage Review Article Bacille-Calmette-Guerin non-responders: how to manage Friedrich-Carl von Rundstedt 1,2, Seth P. Lerner 1 1 Scott of Department of Urology, Translational Biology and Molecular Medicine, Dan

More information

A Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intravesical microwave hyperthermia with intravesical chemotherapy for superficial

More information

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In

More information

ROBOTIC VS OPEN RADICAL CYSTECTOMY

ROBOTIC VS OPEN RADICAL CYSTECTOMY ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to

More information

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish

More information

IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA

IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess

More information

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk

More information

Panel: A Case-based Approach to the Management of Bladder Cancer

Panel: A Case-based Approach to the Management of Bladder Cancer Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Dep. of Urology, Eberhard-Karls University, Tuebingen, Germany Treatment options in HG T1 BCa TUR-BT Primary and second resection (T0-status)

More information

3.1 Investigations for Patients Presenting with Haematuria Table 1

3.1 Investigations for Patients Presenting with Haematuria Table 1 3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements

More information

TARGETING CANCER WITH POWER AND PRECISION

TARGETING CANCER WITH POWER AND PRECISION TARGETING CANCER WITH POWER AND PRECISION T h o m a s C a n n e l l, D. V. M., P r e s i d e n t a n d C E O A u g u s t 9, 2 0 1 8 NASDAQ: SESN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking

More information

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Lymphadenectomy in RCC: Yes, No, Clinical Trial? Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Oral Communications & Posters

Oral Communications & Posters Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica

More information

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy

More information

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney

More information

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after

More information

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No

More information

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.

More information

Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy?

Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy? Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy? 80 patients LNU (n = 40) or ONU (n = 40) CSS (p = 0.2), BRFS (p = 0.86), MFS (p = 0.12) similar for the entire cohort Subgroups of pt3 UTUC

More information

Checkpoint Inibitors for Bladder Cancer

Checkpoint Inibitors for Bladder Cancer Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,

More information

Staging and Grading Last Updated Friday, 14 November 2008

Staging and Grading Last Updated Friday, 14 November 2008 Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty

More information

Research Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C

Research Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C Bladder Cancer 1 (2015) 143 150 DOI 10.3233/BLC-150020 IOS Press Research Report 143 Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer

More information

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008 Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation

More information

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder

More information

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS

MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS This symposium took place on 12 th March 2016 as part of the European Association of Urology Congress 2016 in Munich, Germany

More information

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC. ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in

More information

Guidelines for the Management of Bladder Cancer

Guidelines for the Management of Bladder Cancer Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of

More information

Early radical cystectomy in NMIBC Marko Babjuk

Early radical cystectomy in NMIBC Marko Babjuk Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,

More information

Open Radical Cystectomy Tips and Tricks in Males and Females

Open Radical Cystectomy Tips and Tricks in Males and Females Open Radical Cystectomy Tips and Tricks in Males and Females Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Bladder Cancer. Clinical Case Conference

Bladder Cancer. Clinical Case Conference Bladder Cancer Clinical Case Conference Clinical Case 89 yo M with gross hematuria Labs: Chem: BUN/Cr increased 22/1.27 CBC: H/H 13/36, WBCs wnl UA: >50 RBCs, otherwise wnl UCx: No growth Cystoscopy at

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates

BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates 2181 Treatment Options for Muscle-invasive Urothelial Cancer for Patients Who Were Not Eligible for Cystectomy or Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Report

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer?

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Authors: Roderick Clark, 1 Kevin Wong, 2 Stacy Fan, 2 Joseph Chin, 1,3 Jonathan

More information

Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1

Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1 Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1 Case Study 1 A 22-year-old man with a history of gross total painless hematuria: two times in two months, both after

More information

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma Kamat et al. Journal for ImmunoTherapy of Cancer (2017) 5:68 DOI 10.1186/s40425-017-0271-0 POSITION ARTICLE AND GUIDELINES Society for Immunotherapy of Cancer consensus statement on immunotherapy for the

More information

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy

More information

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean

More information

Urine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia

Urine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Urine Markers for Bladder Cancer Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Disclosures Role Consultant/Speaker Grant Funding Clinical

More information

14th Meeting of the EAU Section of Oncological Urology (ESOU)

14th Meeting of the EAU Section of Oncological Urology (ESOU) Is Bacillus Calmette-Guerin (BCG) still the best adjuvant treatment after Trans Urethral Resection (TUR) for Ta-T1 high grade (G3) bladder cancer M. Brausi, Modena (IT) Introduction Bacillus Calmette-Guerin

More information

THE SEARCH FOR BIOMARKERS IN BLADDER CANCER

THE SEARCH FOR BIOMARKERS IN BLADDER CANCER THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Organ-sparing treatment of invasive transitional cell bladder carcinoma Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

Lymph node dissection: how much is enough?

Lymph node dissection: how much is enough? 1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

TCC recurrence within the upper tract urothelium following

TCC recurrence within the upper tract urothelium following Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup Kristin M. Sanderson,* Jie Cai, Gustavo

More information